Compare PACK & ZVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PACK | ZVRA |
|---|---|---|
| Founded | 1972 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Containers/Packaging | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 303.3M | 472.9M |
| IPO Year | 2017 | 2015 |
| Metric | PACK | ZVRA |
|---|---|---|
| Price | $3.82 | $10.40 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | $6.50 | ★ $23.00 |
| AVG Volume (30 Days) | 325.2K | ★ 665.1K |
| Earning Date | 05-05-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 159.21 |
| EPS | N/A | ★ 1.35 |
| Revenue | ★ $395,000,000.00 | $106,470,000.00 |
| Revenue This Year | $9.29 | $37.27 |
| Revenue Next Year | $8.35 | $53.42 |
| P/E Ratio | ★ N/A | $7.65 |
| Revenue Growth | 7.08 | ★ 350.91 |
| 52 Week Low | $2.91 | $6.85 |
| 52 Week High | $6.31 | $13.16 |
| Indicator | PACK | ZVRA |
|---|---|---|
| Relative Strength Index (RSI) | 49.43 | 64.60 |
| Support Level | $3.33 | $8.29 |
| Resistance Level | $5.78 | $11.19 |
| Average True Range (ATR) | 0.15 | 0.39 |
| MACD | 0.09 | 0.08 |
| Stochastic Oscillator | 83.18 | 88.68 |
Ranpak Holdings Corp is a provider of environmentally sustainable, systems-based, product protection solutions for e-Commerce and industrial supply chains. The company offers a full suite of protective packaging systems and paper consumables. The group generates revenue by providing its PPS systems and paper consumables to customers, which include direct end-users and a network of exclusive paper packaging solution distributors, and by providing end-of-line automation systems that solve challenges, including optimization, customization, and efficiency. It has two segments, North America and Europe/Asia.
Zevra Therapeutics Inc is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. The company's mission is to bring life-changing therapeutics to people living with rare diseases. With data-driven development and commercialization strategies, it is overcoming complex drug development challenges to make new therapies available to the rare disease community.